menu
    • menu

    Company profile for Corcept Therapeutics

    NEW Drugs in Dev: 16
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    we are leading the discovery and development of drugs that modulate the effects of cortisol Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases. Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. C...
    we are leading the discovery and development of drugs that modulate the effects of cortisol Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases. Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Corcept TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    149 Commonwealth Drive Menlo Park, CA 94025
    Telephone
    Telephone
    650-327-3270
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.corcept.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/corcept-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lifyorli Shows Survival Benefit in Resistant Ovarian Cancer
    Lifyorli Shows Survival Benefit in Resistant Ovarian Cancer

    29 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260529589368/en/Corcept-Presents-New-Data-at-ASCO-2026-Lifyorli-Overall-Survival-Across-All-Subgroups-of-Patients-with-Platinum-Resistant-Ovarian-Cancer-Including-Those-with-Recent-Taxane-Exposure

    BUSINESSWIRE
    29 May 2026
    Share Share
    Corcept to Resubmit NDA for Relacorilant in Cushing's Diseases
    Corcept to Resubmit NDA for Relacorilant in Cushing's Diseases

    27 May 2026

    // PRESS RELEASE

    https://ir.corcept.com/news-releases/news-release-details/corcept-resubmit-its-new-drug-application-relacorilant-treatment

    PRESS RELEASE
    27 May 2026
    Share Share
    Corcept's ALS Drug Boosts 2-Year Survival in Phase 3
    Corcept's ALS Drug Boosts 2-Year Survival in Phase 3

    01 May 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/corcept-ties-als-drug-to-improved-2-year-survival-as-phase-3-start-date-nears

    BIOSPACE
    01 May 2026
    Share Share
    Corcept Therapeutics Reveals Q1 Financials & Corporate Progress
    Corcept Therapeutics Reveals Q1 Financials & Corporate Progress

    30 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7257132

    FIRSTWORD PHARMA
    30 Apr 2026
    Share Share
    Corcept Phase 2 Study: Dazucorilant Boosts 2-Year ALS Survival
    Corcept Phase 2 Study: Dazucorilant Boosts 2-Year ALS Survival

    30 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7257414

    FIRSTWORD PHARMA
    30 Apr 2026
    Share Share
    Corcept Therapeutics to Share Q1 Results and Corporate Update
    Corcept Therapeutics to Share Q1 Results and Corporate Update

    23 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260423182131/en/Corcept-Therapeutics-to-Announce-First-Quarter-Financial-Results-Provide-Corporate-Update-and-Host-Conference-Call

    BUSINESSWIRE
    23 Apr 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search